"As we seek FDA clearance for CABA-201 in the next few months, we believe that our specifically designed product candidate for autoimmune patients, our experience with efficient autoimmune cell therapy clinical trial design coupled with timely implementation of complicated autoimmune cell therapy trials and our exclusive translational research partnership with Georg Schett, M.D., which is currently delivering actionable clinical insights, provide us with the opportunity to deliver potentially transformative outcomes for patients with a broad range of autoimmune diseases," said Steven Nichtberger, M.D., Chief Executive Officer and Co-founder of Cabaletta. "In parallel, we continue to make progress on our pipeline of clinical-stage CAART legacy product candidates, with 1-month safety and persistence data for the combination sub-study in the DesCAARTes trial for DSG3-CAART anticipated in the first half of 2023 and recruitment in the MusCAARTes trial for MuSK-CAART ongoing. Looking ahead, we are confident in our ability to advance our autoimmune-focused pipeline for patients with serious unmet need and deliver on multiple upcoming value-creating milestones."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CABA:
- 3 Stocks to Buy Today, 3/17/2023, According to Top Analysts
- Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference
- TipRanks ‘Perfect 10’ List: There’s an Opportunity Brewing in These 2 Stocks
- Cabaletta Bio price target raised to $18 from $14 at Evercore ISI
